Adam's Take By Adam Feuerstein In new remarks, Cassava Sciences’ CEO shifts defense of embattled treatment for Alzheimer’s
Biotech By Matthew Herper, Damian Garde and Adam Feuerstein Newly disclosed FDA documents reveal agency’s unprecedented path to approving Aduhelm
Health By Andrew Joseph Q&A: The CEO of the Alzheimer’s Association on the approval of Aduhelm — and why critics should stop dwelling on the decision
First Opinion By Jason Karlawish If the FDA approves Biogen’s Alzheimer’s treatment, I won’t prescribe it
First Opinion By Jim Taylor Medicare: Cover amyloid PET scans and stop keeping people with dementia in the dark
Biotech By Matthew Herper and Adam Feuerstein Eli Lilly releases detailed results on Alzheimer’s drug, as data divide researchers
Biotech By Matthew Herper, Adam Feuerstein and Damian Garde Expert panel votes down Biogen’s Alzheimer’s drug, and rebukes the FDA in the process
Biotech By Adam Feuerstein ‘Quite puzzling’ results in Alzheimer’s study cloud future of tau-targeting antibody treatment
Biotech By Adam Feuerstein Alzheimer’s conference preview: Aduhelm debate persists, while field grapples with new targets and directions
In the Lab By Megan Molteni Mouse experiments with a decades-old drug suggest a new approach to Alzheimer’s treatment
Biotech By Adam Feuerstein Biogen, Eisai seek fast approval for second Alzheimer’s drug, relying on relaxed FDA standard
Pharma By Adam Feuerstein In reversal, Eli Lilly now intends to seek fast approval for Alzheimer’s treatment
Biotech By Damian Garde and Adam Feuerstein How a scientific journal’s ‘grotesque overreaction’ inflamed the contentious debate over Biogen’s Alzheimer’s drug
Biotech By Adam Feuerstein, Damian Garde and Meg Tirrell An FDA adviser on why his panel took a skeptical view on Biogen’s Alzheimer’s drug
Biotech By Damian Garde and Adam Feuerstein Inside the tense, high-stakes meeting on Biogen’s Alzheimer’s treatment
Pharmalot By Ed Silverman Most doctors view the Biogen Alzheimer’s drug favorably after reading briefing documents, survey finds
Biotech By Damian Garde and Adam Feuerstein FDA scientists appear to offer major endorsement of Biogen’s controversial Alzheimer’s treatment
Biotech By Adam Feuerstein and Damian Garde Your guide on how to prepare for a historic FDA panel meeting on Alzheimer’s
Biotech By Adam Feuerstein A pivotal FDA meeting on Biogen’s Alzheimer’s treatment is near. Here’s what you need to know
Biotech By Adam Feuerstein The FDA accepted Biogen’s Alzheimer’s drug submission. Next up, a highly anticipated outside expert review
Biotech By Damian Garde Two more failed Alzheimer’s drugs sharpen focus on Biogen’s chances for aducanumab
Biotech By Jonathan Saltzman — Boston Globe Startup Arkuda targets rapidly advancing, rare form of dementia
First Opinion By Dennis J. Selkoe Biogen’s good news on aducanumab could ‘open the floodgates’ for Alzheimer’s drugs
In the Lab By Sharon Begley New prize offers $2 million for finding key to Alzheimer’s in past research
Pharmalot By Ed Silverman Pharmalittle: Biogen argues investors overreacted; AstraZeneca wins a key immunotherapy approval
Adam's Take By Adam Feuerstein In biotech, it pays to be bullish on Alzheimer’s trials, even when facts stand in the way
Pharmalot By Ed Silverman FDA is offering a new approach for developing Alzheimer’s drugs. What could that mean?
Health By Damian Garde Fans ‘didn’t care if he messed up’: Glen Campbell’s doctor discusses his struggle with Alzheimer’s